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ABSTRACT
Objectives: Supraclavicular block of brachial plexus provides complete and reliable anesthesia for upper limb surgeries. Using adjuvant to local 
anesthetics, blocks can be prolonged to long durations. Peripheral nerve blocks thus help in avoiding the hazards of general anesthesia. We compared 
the sensory blockade, motor blockade, and duration of analgesia with the addition of fentanyl or dexmedetomidine to bupivacaine for supraclavicular 
brachial plexus block.
Methods: A total of 50 American Society of Anesthesiologist’s Physical Status I and II patients scheduled for elective upper limb surgeries under 
supraclavicular brachial plexus block were divided into two equal groups in a randomized double-blinded fashion. Group BF received 30 ml 
bupivacaine with fentanyl 50 µg and Group BD received 30 ml bupivacaine with dexmedetomidine 50 µg. The characteristics for anesthesia and 
analgesia were assessed in both groups.
Results: Duration of sensory and motor block was 363.4±38.36 minutes and 357±36.77 minutes, respectively, in Group BF while it was 
452.96±77.12 minutes and 441.52±48.46 minutes in Group BD. There was a statistically significant difference in onset of sensory and motor 
block between the two groups. The duration of analgesia (time to requirement of rescue analgesia) in Group BD was longer than in Group BF 
(471.44±65.88 minutes vs. 366.48±38.02 minutes) with (p<0.0001). There were minimum hemodynamic disturbances and side effects in any group 
except for Grade 3 sedation score which was more in Group BD.
Conclusion: Dexmedetomidine, when added to bupivacaine in supraclavicular brachial plexus block, enhanced the duration of sensory and motor 
block and also the duration of analgesia, more than when fentanyl was added to bupivacaine.
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INTRODUCTION
Upper limb surgeries are usually done under peripheral blocks 
such as brachial plexus block. Reduced hospital stay, less financial 
burden, and avoidance of complications due to general anesthesia are 
many advantages of brachial plexus block in comparison to general 
anesthesia. Peripheral nerve blocks not only provide intraoperative 
anesthesia but also post-operative analgesia without any systemic 
side effects [1]. Different adjuvants are used with local anesthetics 
that prolong the duration of anesthesia with less adverse effects. 
Opioids, α2 agonist, and dexamethasone are few of them. Addition 
of fentanyl to local anesthetic is known to significantly improve the 
duration of sensory and motor blockade as well as visual analog scale 
scores [2,3]. Dexmedetomidine, a potent centrally acting α2 agonist, is 
widely used for anesthesia, analgesia, monitored anesthesia care, and 
as an adjuvant to local anesthetic for peripheral nerve block [4,5]. In 
humans, dexmedetomidine has shown to prolong the duration of the 
block and post-operative analgesia when added to local anesthetic in 
various regional blocks [6-9]. The purpose of the study was to examine 
if dexmedetomidine added to bupivacaine enhanced the duration of the 
motor block, sensory block, and duration of analgesia as compared to 
fentanyl in brachial plexus block, thus providing a better alternative to 
opioids.
METHODS
After obtaining ethical committee clearance and written informed 
consent from patients, a double-blinded randomized prospective clinical 
trial was carried out on 50 American Society of Anesthesiologist’s 
Grades I and II patients of either sex aged 20-60 years, undergoing 
various orthopedic surgeries of upper limb under supraclavicular 
brachial plexus block. They were divided into two groups of 25 patients 
each. Patients with known hypersensitivity to local anesthetic drugs, 
bleeding disorders, pre-existing neuropathy, any hepatic, renal, 
neurological, psychiatric, or neuromuscular diseases, and pregnancy/
lactation were excluded from the study.
On arrival in the operation theater, baseline heart rate (HR), blood 
pressure, and saturation were recorded. An intravenous line (IV) was 
secured in the unaffected limb and ringers lactate was started. Injection 
ranitidine and injection midazolam (0.03 mg/kg) were given IV.
Patients were randomly assigned into two groups of 25 each. After 
aseptic preparation of the skin, supraclavicular plexus block was 
performed with the help of nerve stimulator locator. A 22 Gauge 30 mm 
insulated needle (Stimuplex, Braun, Germany) was attached to the 
locator and inserted at an initial current output of 1.5 mA and 2 Hz 
frequency. The location endpoint was a distal motor response with 
an output lower than 0.5 mA in the median nerve region. Following 
negative aspiration 30 ml, local anesthetic was injected. Group BF 
received 30 ml of bupivacaine 0.5% with 50 µg fentanyl and BD received 
30 ml of bupivacaine 0.5% with 50 µg dexmedetomidine. A 3 minutes 
massage was performed to facilitate an even drug distribution.
Assessment of sensory block was done by pinprick method every 
minute after drug injection till complete sensory blockade was achieved 
in distribution of any one major nerve. Sensory onset was considered 
when there was dull sensation to pinprick, and the complete sensory 
block was considered when there was complete loss of sensation to 
pinprick.
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Sensory block was graded as:
• Grade 0: Sharp pain felt
• Grade 1: Analgesia, dull sensation felt
• Grade 2: Anesthesia, no sensation felt.
Assessment of motor block was evaluated using the modified Bromage 
scale. Onset of the block was considered when there was Grade 1i motor 
blockade and complete when Grade 2 block.
Motor block was graded as:
• Grade 0: Normal motor function with full flexion and extension of 
elbow wrist and fingers
• Grade 1: Decreased motor strength with ability to move fingers only
• Grade 2: Complete motor block with inability to move fingers.
The block was considered failed if any anesthesia was found to be 
inadequate in any major nerve distribution even after 30 minutes of 
drug injection and were excluded from the study.
The duration of sensory block was defined as the time interval between 
the end of the local anesthetic administration and the complete 
resolution of anesthesia of all nerves. The duration of motor block was 
defined as the time interval between the end of the local anesthetic 
administration and the recovery of complete motor function of the 
hand and forearm. Patients were assessed for pain as per numerical 
rating scale of 1-10. It was recorded every 60 minutes till score of 5. 
Rescue analgesia was immediately administered (diclofenac sodium 
1.5 mg/kg IV) at such point. Duration of analgesia was calculated from 
the time of sensory onset to first dose of rescue analgesia.
All patients were observed for any side effects such as nausea, vomiting, 
dryness of mouth, itching, sedation, side effects of block like respiratory 
distress due to pneumothorax, Horner’s syndrome, and recurrent 
laryngeal nerve palsy. Hypotension was defined as fall in mean arterial 
pressure >20% of baseline value and bradycardia when HR ≤50/minutes. 
This was corrected with 100 ml fluid bolus or ephedrine 6 mg if 
required and IV atropine 0.6 mg, respectively. Degree of sedation was 
monitored using Ramsay sedation scale (1: Awaken and alert, 2: Sedated 
but responding to mild physical stimuli, 3: Sedated but responding to 
moderate or strong physical stimulus, and 4: Not arousable).
At the end of procedure, quality of anesthesia was graded as Grade IV 
(excellent) - no complaint from the patient; Grade III (good) - Minor 
complaint from the patient that did not require supplemental analgesics; 
Grade II (moderate) - Complaint that required supplemental analgesics; 
Grade I (unsuccessful) L - Patients required general anesthesia.
RESULTS
About 50 patients posted for upper limb surgeries were randomly 
divided into two groups, BF and BD, of 25 each. Both groups were 
comparable in terms of age, gender, weight, and type of surgeries 
(p>0.001) (Table 1).
Onset of sensory block was faster in Group BD (2.108±0.68 minutes) 
than in Group BF (8.4±1.27 minutes), with p<0.0001 (Table 2). Onset of 
motor block was 9.088±1.81 and 4.504±1.31 minutes in Groups BF and 
BD, respectively (p<0.0001).
Duration of sensory block was 452.96±77.12 minutes in Group BD as 
compared to 363.4±38.36 minutes in Group BF. The duration of motor 
block was 441.52±48.46 minutes in Group BD, whereas 357±36.77 
minutes in Group BF. Significantly longer duration of sensory and 
motor blockade was observed in Group BD than Group BF (p<0.0001) 
(Table 2).
There was significant increase in duration of analgesia in Group BD 
(471.44±65.88 minutes) as compared to Group BF (366.48±38.02 
minutes), and the difference was statistically significant (Table 2) 
(p<0.0001)
Quality of anesthesia was excellent in Group BD, 22 patients achieved 
Grade IV quality block and only 3 patients required sedation or 
sedation with analgesia, whereas in Group BF, 11 patients achieved 
Grade IV quality of block and 1 patient required general anesthesia due 
to inadequate block (p=0.001) (Table 3).
No episode of respiratory depression or hypoxemia was observed in 
any patients intraoperatively or 24 hrs postoperatively. Bradycardia 
was found in 3 patients of Group BD and none in Group BF. Nausea and 
vomiting were found in 2 and 1 patient in Group BD and BF, respectively. 
Sedation score of 3 was most often noted in Group BD (15 patients) 
compared to Group BF, which was statistically significant (p=0.0001). 
Technical complications of the block such as hematoma, pneumothorax, 
and Horner’s syndrome were not noted in any patient during the study 
(Table 4).
Statistical analysis
The data were analyzed by SPSS 20 software. Unpaired t-test was 
applied for demographic data, hemodynamic parameters, onset and 
duration of sensory and motor blockade, and duration of analgesia. 
Table 1: Demographic data
Variables n=25 p
Group BF Group BD
Age (years) 34.68±8.70 34.96±8.59 0.909
Sex (M/F) 16/9 19/6
Weight (kg) 56.08±4.57 56.4±4.93 0.813
Type of operation
Olecranon 10 11
Lower end humerus 9 7
Radius, ulna 6 7
Values are expressed in mean±SD. n: Number of patients, M: Male, F: Female, 
Kg: Kilograms, SD: Standard deviation, BF: Bupivacaine with fentanyl, 
BD:  Bupivacaine with dexmedetomidine
Table 2: Characteristics of blockade
Group BF Group BD
Onset of sensory 
block (minutes)
8.4±1.27 2.108±0.68 <0.0001
Duration of sensory 
block (minutes)
363.4±38.36 452.96±77.12 <0.0001
Onset of motor 
block (minutes)
9.088±1.81 4.504±1.31 <0.0001






Values are expressed in mean±SD. n: Number of patients, SD:  Standard 
deviation, BF: Bupivacaine with fentanyl, BD: Bupivacaine 
with  dexmedetomidine
Table 3: Incidence of side effects
Side effects n=25 p
Group BF Group BD
Hypotension 1 - 0.322
Bradycardia - 3 0.076
Sedation (Grade 3) - 15 0.0001
Respiratory depression - -
Nausea, vomiting 2 1 0.56
Pruritus 1 - 0.322
Pneumothorax - -
Horner syndrome - -
BF: Bupivacaine with fentanyl, BD: Bupivacaine with dexmedetomidine
n=25 p
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Fisher exact test was applied for assessment of quality of block. p value 
was considered significant if <0.05 and highly significant if <0.001.
DISCUSSION
Brachial plexus block has proved to be a better alternative to general 
anesthesia for upper limb surgeries. With addition of adjuvant to local 
anesthetics block can be prolonged to cover lengthy surgeries. Out of all 
the available options, the α2 adrenergic receptor agonist-like clonidine 
and dexmedetomidine has proved to be better alternatives to other 
adjuvants such as opioids. Though addition of fentanyl enhances post-
operative analgesia, the duration of this effect is too brief to be clinically 
useful which was stated Kardas et al. [11] and was in congruence 
with our observation. Karakaya et al. [12] observed that 100 µg/kg 
fentanyl added in axillary brachial plexus produced no difference in 
block characteristics of bupivacaine 0.25% and increased the incidence 
of side effects such as nausea and vomiting, though post-operative 
analgesia was doubled. Supportive observation in increase in duration 
of sensory and motor block with post-operative analgesia has also been 
observed in studies by Geze et al. [13], Madhusudan et al. [2], Sindjelic 
et al. [14], and Chavan et al. [15]. In 2000, Nisikawa et al. found that 
addition of fentanyl to axillary blocks with lidocaine plus epinephrine 
increase block duration by approximately 1 hr but delayed block onset 
in all branches. It was speculated that this delay in onset of action of 
fentanyl was caused by differences in pH of the injectates [3].
Various studies were done with clonidine as adjuvant to the local 
anesthetic. El Saied et al. conducted a study, in which axillary 
brachial plexus blockade was performed with addition of clonidine 
to ropivacaine [16]. The study showed that addition resulted in 
prolongation of sensory and motor block and analgesia without 
increased incidence of side effects. In another study, Cucchiaro and 
Ganesh evaluated the effects of clonidine on the duration of sensory 
and motor block and analgesia in children in various peripheral 
nerve blocks including brachial block and concluded that addition 
of clonidine to either bupivacaine or ropivacaine can extend sensory 
and motor blocks [17]. Dexmedetomidine, an α2 adrenergic receptor 
agonist, acts like clonidine. It is highly specific and selective to α2 
receptors. It has been successfully utilized in various anesthetic 
techniques due to hemodynamic stabilizing properties, sedative, 
analgesic, and sympatholytic effects [18]. Highly lipophilic nature 
of dexmedetomidine allows rapid absorption into the cerebrospinal 
fluid and binding to α2 receptors of the spinal cord for its analgesic 
action.
The action of dexmedetomidine on the α2 receptors in the locus 
coeruleus and dorsal horn of spinal cord reduces central sympatholytic 
output, resulting in increased firing of inhibitory neurons, and hence, 
producing analgesia is a known feature. Peripheral α2 receptors may also 
provide antinociception. The inhibitory action of α2 receptor agonist is 
expressed by hyperpolarization of cell membrane and decreased firing 
of excitable cells of the central nervous system. Reduction of calcium 
conductance into cells, thus inhibiting neurotransmitter release is other 
prominent physiologic actions ascribed to α2 adrenoceptors. The nerve 
is prevented from firing, and it also prevents propagation of signals 
to the neighbors, providing analgesia in two different ways [19-21]. 
Peripheral analgesic [22] action of dexmedetomidine is due to its 
binding to α2 A adrenergic receptor.
Marhofer et al. reported a profound prolongation of ulnar nerve 
block (UNB) of 60% with perineural dexmedetomidine when added 
to 0.75% ropivacaine, whereas systemic administration of 20 µg 
dexmedetomidine resulted in a prolongation of only 10% during UNB 
with 0.75% ropivacaine [23]. Esmaoglu et al. added dexmedetomidine 
to levobupivacaine for axillary brachial plexus block and showed that 
it shortens the onset time of both motor and sensory block, prolongs 
the duration of block and the duration of post-operative analgesia [8]. 
Agarwal et al. compared the effects of adding dexmedetomidine to 
bupivacaine in supraclavicular brachial plexus block in 50 patients [24]. 
They concluded that dexmedetomidine added as an adjuvant to 
bupivacaine for supraclavicular brachial plexus block significantly 
shortens the onset time and prolongs the duration motor and sensory 
block and duration of analgesia. Patients in dexmedetomidine group 
were adequately sedated with no adverse effects except bradycardia 
in one. It coincides with the result of our study. Memis et al. in their 
study showed that addition of dexmedetomidine to lignocaine for IV 
regional anesthesia improves both qualities of anesthesia as well as 
intraoperative and post-operative analgesia [7].
The present study is a randomized double-blinded study, where we 
compared addition of injection fentanyl 50 µg and dexmedetomidine 50 µg 
to bupivacaine in supraclavicular brachial plexus block and found that 
that there was significantly increased the duration of sensory and motor 
blockade in the dexmedetomidine group than the fentanyl group. In our 
study, 22 patients (88%) in Group, BD achieved Grade 4 block, i.e., excellent 
block without any supplementary analgesia or sedation, whereas only 
11 patients (44%) in Group BF achieved Grade 4 quality. This improved 
quality of block might be the result of various mechanisms of nerve 
conduction block such as hyperpolarization [25], decreased CAP [26], 
and inhibition of voltage-gated sodium pump by dexmedetomidine. A 
significant prolongation in surgical anesthetic and analgesic duration in 
patients receiving adjuvant - dexmedetomidine as observed in our study, 
lend support to various studies by Ammar and Mahmoud [4], Esmaoglu 
et al., [8] Gandhi et al., [27] and Kathuria et al.  [28] with the use of 
dexmedetomidine in dose ranging from 50 to 100 µg.
Hemodynamic parameters were similar in all groups. No respiratory 
depression, fall in SpO2 was observed in any patient of either study 
groups. Hypotension was noted in one patient in Group BF, bradycardia 
in 3 patients of Group BD. This negative chronotropic effect of 
dexmedetomidine did not require any anticholinergic drug therapy. 
Abdallah and Brull in the meta-analysis of perineural application 
of dexmedetomidine as a local anesthetic adjuvant stated that 
dexmedetomidine produced reversible bradycardia in 7% of brachial 
plexus block patients with no incidence of hypotension [29] Incidence 
of nausea and vomiting were 2 in Group BF versus 1 in BD group. Itching 
was observed in 1 patients receiving fentanyl as adjuvant. It is unlikely 
to have systemic side effects with perineural administration of drugs, 
but the systemic absorption of the drug may have a central effect. Side 
effect profile of both groups did not exhibit any significant difference. 
None of the patients in Group BD required sedation intraoperatively, and 
they were comfortable throughout the surgery with arousable sedative 
effects and it resolved with the recession of block. Achievement of score 
3 sedation with the lack of hemodynamic or any other side effect, can 
make 50 µg dexmedetomidine an attractive choice for supraclavicular 
brachial plexus block.
From this study, we would like to suggest that dexmedetomidine can be 
safely used with local anesthetics in various peripheral nerve blocks; 
however, further studies required to know the exact dose and any 
neurotoxic effect on the human nerve.
CONCLUSION
To conclude, we would like to state that dexmedetomidine besides 
shortening the onset time of block, prolongs the duration of sensory and 
motor block, post-operative analgesia and enhances the quality of block 
as compared with fentanyl when used as an adjuvant to bupivacaine in 
supraclavicular brachial plexus block without any significant side effect.
Table 4: Quality of block
Quality of block n=25 (%) p
Group BF Group BD
Grade 1 1 (4) - 0.001
Grade 2 6 (24) 1 (4)
Grade 3 7 (28) 2 (8)
Grade 4 11 (44) 22 (88)
BF: Bupivacaine with fentanyl, BD: Bupivacaine with dexmedetomidine
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